共 100 条
[1]
Forouzanfar MH(2016)Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015 Lancet 388 1659-1724
[2]
Afshin A(2006)Worldwide epidemic of hypertension Can J Cardiol 22 553-555
[3]
Alexander LT(1995)Hypertension prevalence, awareness, treatment, and control in Egypt. Results from the Egyptian National Hypertension Project (NHP). NHP Investigative Team Hypertension 26 886-890
[4]
Chockalingam A(2011)Percutaneous renal denervation for the treatment of resistant essential hypertension; the first Dutch experience Netherlands Hear J 19 319-323
[5]
Campbell NR(2013)Problem of hypertension in Egypt Egypt Hear J 65 233-234
[6]
Fodor JG(2018)2018 ESC/ESH Guidelines for the management of arterial hypertension Eur Heart J 39 3021-3104
[7]
Ibrahim MM(2002)The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT) JAMA 288 2981-2997
[8]
Rizk H(2009)Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42trials Am J Med 122 290-300
[9]
Appel LJ(2011)Patient and general practitioner attitudes to taking medication to prevent cardiovascular disease after receiving detailed information on risks and benefits of treatment: a qualitative study BMC Fam Pract 12 59-700
[10]
Voskuil M(2017)Peroxisome proliferator-activated receptors as therapeutic targets for heart failure Biomed Pharmacother 95 692-635